Rx00065 - Clindamycin


Name:
Clindamycin
Rx ID:
Rx00065
Validation Level:
Phenomic Similarity:
0.544
Reference ID:
DB01190
Primary Indications:
Pneumocystis carinii pneumonia; Acquired Immunodeficiency Syndrome; sarcoidosis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Infections
Drug Interactions:
Aluminium; Atracurium; Attapulgite; Cyclosporine; Dihydroxyaluminium; Doxacurium chloride; Kaolin; Metocurine; Mivacurium; Pancuronium; ...
Click to show more...
Food Interactions:
Take with food.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00065
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
SARCOIDOSIS INFECTIONS 1.1e-15 CCL3, CCR5, CD14, CDKAL1, CTLA4, HLA-B, HLA-C, IFNB1, IFNG, IL10, IL1A, IL1B, IL4, IL6, NOD2, NOS3, PPARG, PPARGC1A, TLR2, TLR4, TLR9, TNF

Chemical, Pharmacological and Biological Annotations


ATC Code:
D10AF01; G01AA10 J01FF01;
Brands:
Clindets (Perrigo); Clinimycin (Hayat); Dalacin C (Pfizer); Dalacin T Topical Solution (Pfizer); Zindaclin (Crawford)
Categories:
Anti-Bacterial Agents; Protein Synthesis Inhibitors; Antibiotics
ChEBI ID:
3745
PubChem ID:
29029
KEGG Drug ID:
D00277
SMILE:
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
InChI:
1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids and Derivatives
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infe...
Click to show more...
Pharmacodynamics:
Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
Description:
Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be ba...
Click to show more...
Mechanism:
Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentration...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.3192 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org